{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:28:43Z","timestamp":1793975323453,"version":"4.8.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0210073"],"award-info":[{"award-number":["JP20fk0210073"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015993","name":"Kowa Company Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015993","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Government of Japan Ministry of Education Culture Sports Science and Technology","doi-asserted-by":"publisher","award":["19K08975"],"award-info":[{"award-number":["19K08975"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemistry and Biophysics Reports"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bbrep.2026.102784","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:00:55Z","timestamp":1789362055000},"page":"102784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Distinct metabolomic signatures of SGLT2 inhibitor vs. sulfonylurea in a paired human liver biopsy study"],"prefix":"10.1016","volume":"48","author":[{"given":"Yumie","family":"Takeshita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1155-9080","authenticated-orcid":false,"given":"Hein Ko","family":"Oo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1620-7164","authenticated-orcid":false,"given":"Yujiro","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Tsujiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyoshi","family":"Soga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4393-3244","authenticated-orcid":false,"given":"Toshinari","family":"Takamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrep.2026.102784_bib1","doi-asserted-by":"crossref","unstructured":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol. 81, 492\u2013542. doi: 10.1016\/j.jhep.2024.04.031.","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"10.1016\/j.bbrep.2026.102784_bib2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2337\/dc09-0148","article-title":"Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis","volume":"33","author":"Hamaguchi","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bbrep.2026.102784_bib3","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2337\/db22-0933","article-title":"Trajectories of liver fibrosis and gene expression profiles in nonalcoholic fatty liver disease associated with diabetes","volume":"72","author":"Sako","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.bbrep.2026.102784_bib4","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000423","article-title":"Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction-associated steatohepatitis","volume":"8","author":"Younossi","year":"2024","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.bbrep.2026.102784_bib5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.bbrep.2026.102784_bib6","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.cgh.2022.04.014","article-title":"Mortality outcomes by fibrosis stage in Nonalcoholic Fatty liver disease: a systematic review and meta-analysis","volume":"21","author":"Ng","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrep.2026.102784_bib7","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.2337\/dc21-2049","article-title":"Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial","volume":"45","author":"Takeshita","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bbrep.2026.102784_bib23","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/s41598-024-52603-5","article-title":"Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis","volume":"14","author":"Ong Lopez","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrep.2026.102784_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104342","article-title":"Liver autophagy-induced valine and leucine in plasma reflect the metabolic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin","volume":"86","author":"Furuya","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bbrep.2026.102784_bib9","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.164296","article-title":"Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition","volume":"8","author":"Kogot-Levin","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbrep.2026.102784_bib10","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.cell.2015.01.012","article-title":"Hepatic acetyl-CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes","volume":"160","author":"Perry","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.bbrep.2026.102784_bib11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/ajh\/hpae092","article-title":"State-of-the-Art-Review: mechanisms of action of SGLT2 inhibitors and clinical implications","volume":"37","author":"Vallon","year":"2024","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.bbrep.2026.102784_bib12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrep.2026.102784_bib13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41586-018-0353-2","article-title":"Accumulation of succinate controls activation of adipose tissue thermogenesis","volume":"560","author":"Mills","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bbrep.2026.102784_bib14","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.bbrc.2018.01.106","article-title":"Succinate induces hepatic fibrogenesis by promoting activation, proliferation, and migration, and inhibiting apoptosis of hepatic stellate cells","volume":"496","author":"Park","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrep.2026.102784_bib15","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3803\/EnM.2022.1530","article-title":"Gemigliptin alleviates succinate-induced hepatic stellate cell activation by ameliorating mitochondrial dysfunction","volume":"37","author":"Nguyen","year":"2022","journal-title":"Endocrinol. Metab."},{"key":"10.1016\/j.bbrep.2026.102784_bib16","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.2337\/dc19-0114","article-title":"Preoperative circulating succinate levels as a biomarker for diabetes remission after bariatric surgery","volume":"42","author":"Ceperuelo-Mallafr\u00e9","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bbrep.2026.102784_bib22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/nu16010119","article-title":"Stepwise discovery of insulin effects on amino acid and protein metabolism","volume":"16","author":"Tessari","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.bbrep.2026.102784_bib17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41581-020-00350-x","article-title":"Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation","volume":"17","author":"Marton","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.bbrep.2026.102784_bib18","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s13300-020-00762-9","article-title":"Study protocol for pleiotropic effects and safety of sodium-glucose cotransporter 2 inhibitor versus sulfonylurea in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"11","author":"Takeshita","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.bbrep.2026.102784_bib19","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1021\/pr034020m","article-title":"Quantitative metabolome analysis using capillary electrophoresis mass spectrometry","volume":"2","author":"Soga","year":"2003","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bbrep.2026.102784_bib20","doi-asserted-by":"crossref","first-page":"16768","DOI":"10.1074\/jbc.M601876200","article-title":"Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption","volume":"281","author":"Soga","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrep.2026.102784_bib21","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1021\/ac900675k","article-title":"Metabolomic profiling of anionic metabolites by capillary electrophoresis mass spectrometry","volume":"81","author":"Soga","year":"2009","journal-title":"Anal. Chem."}],"container-title":["Biochemistry and Biophysics Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580826003444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580826003444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:11:56Z","timestamp":1793974316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405580826003444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":23,"alternative-id":["S2405580826003444"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrep.2026.102784","relation":{},"ISSN":["2405-5808"],"issn-type":[{"value":"2405-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct metabolomic signatures of SGLT2 inhibitor vs. sulfonylurea in a paired human liver biopsy study","name":"articletitle","label":"Article Title"},{"value":"Biochemistry and Biophysics Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrep.2026.102784","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102784"}}